☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
seagen
Seagen and Astellas Report P-III Trial (EV-302) Results of Padcev (enfortumab vedotin-ejfv) and Keytruda for Advanced Bladder Canc...
September 22, 2023
Seagen Highlighted German Hodgkin Study Group Presents P-III Trial (HD21) Results of Adcetris (brentuximab vedotin) for Advanced C...
June 21, 2023
Seagen Reports Results from Part C of P-II Trial (SGN35-027) for Adcetris (brentuximab vedotin) to Treat Early-Stage Classical Hod...
June 13, 2023
PharmaShots' Key Highlights of First Quarter 2023
April 3, 2023
Seagen Receive the US FDA’s Accelerated Approval of Tukysa (tucatinib) for RAS Wild-Type, HER2-Positive Metastatic Colorectal Canc...
January 20, 2023
Seagen Entered into an Exclusive License Agreement with LAVA Therapeutics for LAVA-1223 to Treat EGFR-Expressing Solid Tumors
September 27, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.